ClinicalTrials.gg
Sign In

Urinary Bladder Neoplasms clinical trials

The registry lists 1,798 studies for Urinary Bladder Neoplasms across more than 10 countries. 445 are recruiting or about to start. 1,196 of them are mainly about Urinary Bladder Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Non-Muscle Invasive Bladder Neoplasms too: 1,944 studies, 517 open.

ClinicalTrials.gov finds 2,162 studies for Urinary Bladder Neoplasms. How that becomes 1,795 here

This page counts the studies the registry files under Urinary Bladder Neoplasms, and those it files under no condition that list Urinary Bladder Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 2,162Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −139Filed under a narrower condition, counted on its own pageNon-Muscle Invasive Bladder Neoplasms 138
  3. −52List Urinary Bladder Neoplasms as a condition, but the registry did not file them under itMost often written as “Gall Bladder Cancer” (26), “Muscle Invasive Bladder Cancer” (4), and “Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)” (3). The registry filed them under other conditions only, most often Gallbladder Neoplasms (30) and Cholangiocarcinoma (15).
  4. −236Match it another way48 name it in the title, 8 in a keyword, and 180 by a synonym or other text the search reads.
  5. 1,735Counted here and found by its search5 of them list Urinary Bladder Neoplasms in their own words; the registry filed them under no condition.
  6. +60
    Counted here, but its search does not find themThe first 20 of 60.
  7. 1,795The count on this page

Get an email when these change. Save the Urinary Bladder Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
760
Recruiting
336
Status unknown
195
Terminated
182
Active, not recruiting
150
Not yet recruiting
95

Phase

Phase 2
547
Phase 1
371
Phase 3
171
Phase 4
29
Early Phase 1
25

Where

United States
881
China
193
France
159
Canada
154
United Kingdom
141
Spain
137

Who runs them

National Cancer Institute (NCI) (67) · Memorial Sloan Kettering Cancer Center (47) · M.D. Anderson Cancer Center (32) · Mansoura University (27) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (21) · Assiut University (20) · AstraZeneca (19) · Merck Sharp & Dohme LLC (17)

What is being tested here

Drugs under test in Urinary Bladder Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Gemcitabine1213100
Pembrolizumab10735
Enfortumab vedotin10519
Cisplatin51166
Mitomycin5826
Docetaxel5020
Disitamab vedotin527
Durvalumab4319
Nivolumab3425
BCG Vaccine3819

Drug classes tested here Immune checkpoint inhibitors 35 open · Antibody-drug conjugates (ADCs) 23 open · Antimetabolites 15 open · Tyrosine kinase inhibitors (TKIs) 6 open · Antimitotic agents 6 open

Coming up

59phase 3 studies under way
179studies finish main data collection within a year8 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger. 22 (7%) take children under 18. 3 (1%) are for women only and 7 (2%) for men only; 21 (6%) take healthy volunteers.

Recruiting studies that take each age, of 336
AgeWomenMen
1020 (6%)20 (6%)
18304 (90%)306 (91%)
30315 (94%)318 (95%)
40320 (95%)323 (96%)
50324 (96%)328 (98%)
65329 (98%)333 (99%)
75327 (97%)330 (98%)
85290 (86%)293 (87%)

Across all 1,798 studies, recruiting or not: 6% stop at 75 or younger and 1% at 65; 7% take children; 1% are for women only and 3% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Urinary Bladder Neoplasms studies take

Of 194 phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 52 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 143 mo29–66 · 145 studies43 mo30–66 · 80 studies47 mo26–65 · 65 studies
Phase 1/252 mo35–78 · 67 studies45 mo32–74 · 39 studies—
Phase 252 mo36–91 · 194 studies36 mo25–52 · 39 studies58 mo39–103 · 155 studies
Phase 365 mo40–87 · 73 studies54 mo24–74 · 39 studies—
Interventional, no phase39 mo20–69 · 244 studies—40 mo21–70 · 235 studies
Observational60 mo32–… · 202 studies—60 mo30–… · 167 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 11, 2026.

Started recruiting5

Results posted2

Stopped2

Newly registered13

Show 8 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,798. Browse all 1,798 → or search them.